Affibody Ab

Swedish Orphan Biovitrum Ab (publ)

General Electric Company

Ipc Research, LLC

Malin Lindborg

Elin Gunneriusson

Joachim Feldwisch

Patrik Strömberg

Caroline Ekblad

Charlotta Berghard

Magnus Berglund

Torbjörn Gräslund

Johan Seijsing

Faisal Ahmed Syud

Lars B Abrahmsen

Christofer Lendel

Brian Duh-Lan Lee

Michael Ernest Marino

John Löfblom

Rong Zhang

Fredrik Frejd

Lars Abrahmsén

Jason William Castle

Paul Schaffer

Erik Nordling

Joakim Nilsson

Lindvi Gudmundsdotter

John Löblom

Christopher Lendel

Robert Svensson

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EXXXXXXEIXXLPNLXRXQYXAFIXXLXD. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

IL-IR-I binding polypeptide

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EXXXA XXEID XLPNL XXXQW XAFIXXLXD, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.

Polypeptides binding to human complement C5

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Polypeptides

The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Neonatal Fc receptor binding dimer and methods of use

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX(SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EXXXA XXEID XLPNL XXXQW XAFIXXLXD, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.

The invention provides a platelet derived growth factor receptor beta (PDGF-R&#x3b2;) binding polypeptide, comprising a platelet derived growth factor receptor beta binding motif, PBM, which motif consists of an amino acid sequence as defined herein, wherein the PDGF-R&#x3b2;-binding polypeptide binds to PDGF-R&#x3b2; such that the Kvalue of the interaction is at most 1&#xd7;10M. Also provided are methods and uses of said polypeptide in treatment and diagnosis of PDGF-R&#x3b2;-related conditions.

Polypeptide derived from protein A and able to bind PDGF

Provided herein are methods of reducing liver uptake in vivo of a polypeptide that specifically binds to a target comprising: (a) providing a polypeptide that specifically binds to a target; and (b) substituting at least one basic or at least one neutral amino acid residue of the native polypeptide from step (a) with an acidic amino acid residue to produce a modified polypeptide, wherein the modified polypeptide demonstrates an isoelectric point at least 0.05-0.1 pH points less than the isoelectric point of the native polypeptide. Also provided are polypeptides made using the inventive methods as well as imaging techniques that employ the methods and agents.

Biokinetics of fast-clearing polypeptides

Provided herein are PDGF-R&#x3b2; imaging agents that are polypeptides labeled with a signal generator (e.g., paramagnetic label, a radionuclide, or a fluorophore), wherein the imaging agents bind specifically to PDGFR-&#x3b2;. Also provided are in vivo imaging methods using the imaging agents.

PDGF-R&#x3b2; binders

Growing community of inventors

Bromma, Sweden

Malin Lindborg